{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:42:09Z","timestamp":1792665729500,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Interleukin-10 (IL-10) is a central anti-inflammatory cytokine that suppresses immune responses in myeloid cells but can also activate T cells, limiting its therapeutic use in chronic inflammatory diseases owing to narrow efficacy windows and dose-limiting toxicities\n                    <jats:sup>1\u20135<\/jats:sup>\n                    . Here we show that myeloid and T cells differ in their dependence on JAK-family kinase pairing for IL-10 signalling and function. We took advantage of this differential kinase dependence to engineer a tetravalent nanobody-based myeloid-selective IL-10 receptor agonist (msIL-10R agonist) that fully recapitulates IL-10\u2019s potent suppression of monocytes, macrophages and dendritic cells while avoiding stimulation of T cells. Cryo-electron microscopy structural analysis reveals a distinct receptor cross-linking geometry of the msIL-10R agonist compared with native IL-10 family cytokines. This tetravalent architecture renders signalling strictly TYK2-dependent and highly sensitive to IL-10R\u03b1 and IL-10R\u03b2 receptor abundance, thereby conferring selective activity in myeloid cells. This msIL-10R agonist reduces inflammation in humanized mouse models of lipopolysaccharide challenge, delayed-type hypersensitivity and colitis. A humanized version exhibits IgG-like pharmacokinetics, sustained receptor occupancy and durable myeloid suppression up to 30\u2009days without T cell activation or haematological toxicities in non-human primates. These findings establish a geometry-based strategy for achieving cell-type-selective cytokine signalling and identify the msIL-10R agonist as a therapeutic candidate for myeloid-driven inflammatory diseases, including inflammatory bowel diseases.\n                  <\/jats:p>","DOI":"10.1038\/s41586-026-11176-1","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:43:30Z","timestamp":1792039410000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineered TYK2 dependence enables myeloid-selective IL-10 receptor agonism"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1657-9120","authenticated-orcid":false,"given":"D. Alejandro","family":"Canaria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0488-5590","authenticated-orcid":false,"given":"Trang T. T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-4823","authenticated-orcid":false,"given":"Huang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5045-3644","authenticated-orcid":false,"given":"Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9579-933X","authenticated-orcid":false,"given":"Lili","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoa","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2426-8733","authenticated-orcid":false,"given":"Kerul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimei","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayamary Divya","family":"Ravichandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9641-335X","authenticated-orcid":false,"given":"Cong","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4330-9476","authenticated-orcid":false,"given":"George","family":"Delidakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8681-0480","authenticated-orcid":false,"given":"Andrew","family":"Pae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0264-7647","authenticated-orcid":false,"given":"Ramsay","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan C.","family":"Main","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanali","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8056-9464","authenticated-orcid":false,"given":"Maria L.","family":"Mouchess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdeleine","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6322-4165","authenticated-orcid":false,"given":"Ellen M.","family":"McGlinchey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2965-4262","authenticated-orcid":false,"given":"Nicole","family":"Schirle Oakdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan L.","family":"Koleske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0532-920X","authenticated-orcid":false,"given":"Chingwei V.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3862-062X","authenticated-orcid":false,"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2959-4979","authenticated-orcid":false,"given":"Tangsheng","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"11176_CR1","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.immuni.2019.03.020","volume":"50","author":"W Ouyang","year":"2019","unstructured":"Ouyang, W. & O\u2019Garra, A. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity 50, 871\u2013891 https:\/\/doi.org\/10.1016\/j.immuni.2019.03.020 (2019).","journal-title":"Immunity"},{"key":"11176_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109887","volume":"37","author":"A Cardoso","year":"2021","unstructured":"Cardoso, A. et al. Interleukin-10 induces interferon-\u03b3-dependent emergency myelopoiesis. Cell Rep. 37, 109887 https:\/\/doi.org\/10.1016\/j.celrep.2021.109887 (2021).","journal-title":"Cell Rep."},{"key":"11176_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/s0162-3109(98)00058-7","volume":"41","author":"RD Huhn","year":"1999","unstructured":"Huhn, R. D. et al. Effects of single intravenous doses of recombinant human interleukin-10 on subsets of circulating leukocytes in humans. Immunopharmacology 41, 109\u2013117 https:\/\/doi.org\/10.1016\/s0162-3109(98)00058-7 (1999).","journal-title":"Immunopharmacology"},{"key":"11176_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.829063","volume":"13","author":"Z Yang","year":"2022","unstructured":"Yang, Z. et al. Application of pharmacokinetic\/pharmacodynamic modeling to bridge mouse antitumor efficacy and monkey toxicology data for determining the therapeutic index of an interleukin-10 Fc fusion protein. Front. Pharmacol. 13, 829063 https:\/\/doi.org\/10.3389\/fphar.2022.829063 (2022).","journal-title":"Front. Pharmacol."},{"key":"11176_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1136\/gut.50.2.191","volume":"50","author":"H Tilg","year":"2002","unstructured":"Tilg, H. et al. Treatment of Crohn\u2019s disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 50, 191\u2013195 https:\/\/doi.org\/10.1136\/gut.50.2.191 (2002).","journal-title":"Gut"},{"key":"11176_CR6","doi-asserted-by":"publisher","unstructured":"Saraiva, M., Vieira, P. & O\u2019Garra, A. Biology and therapeutic potential of interleukin-10. J. Exp. Med. 217, e20190418 https:\/\/doi.org\/10.1084\/jem.20190418 (2020).","DOI":"10.1084\/jem.20190418"},{"key":"11176_CR7","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1056\/NEJMoa0907206","volume":"361","author":"EO Glocker","year":"2009","unstructured":"Glocker, E. O. et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361, 2033\u20132045 https:\/\/doi.org\/10.1056\/NEJMoa0907206 (2009).","journal-title":"N. Engl. J. Med."},{"key":"11176_CR8","doi-asserted-by":"publisher","first-page":"27954","DOI":"10.1074\/jbc.271.44.27954","volume":"271","author":"RM Weber-Nordt","year":"1996","unstructured":"Weber-Nordt, R. M. et al. Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J. Biol. Chem. 271, 27954\u201327961 https:\/\/doi.org\/10.1074\/jbc.271.44.27954 (1996).","journal-title":"J. Biol. Chem."},{"key":"11176_CR9","doi-asserted-by":"publisher","first-page":"16513","DOI":"10.1074\/jbc.274.23.16513","volume":"274","author":"JK Riley","year":"1999","unstructured":"Riley, J. K., Takeda, K., Akira, S. & Schreiber, R. D. Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J. Biol. Chem. 274, 16513\u201316521 https:\/\/doi.org\/10.1074\/jbc.274.23.16513 (1999).","journal-title":"J. Biol. Chem."},{"key":"11176_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s1074-7613(00)80005-9","volume":"10","author":"K Takeda","year":"1999","unstructured":"Takeda, K. et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10, 39\u201349 https:\/\/doi.org\/10.1016\/s1074-7613(00)80005-9 (1999).","journal-title":"Immunity"},{"key":"11176_CR11","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.4049\/jimmunol.146.10.3444","volume":"146","author":"DF Fiorentino","year":"1991","unstructured":"Fiorentino, D. F. et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146, 3444\u20133451 (1991).","journal-title":"J. Immunol."},{"key":"11176_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7131","volume":"6","author":"B Li","year":"2015","unstructured":"Li, B. et al. IL-10 engages macrophages to shift Th17 cytokine dependency and pathogenicity during T-cell-mediated colitis. Nat. Commun. 6, 6131 https:\/\/doi.org\/10.1038\/ncomms7131 (2015).","journal-title":"Nat. Commun."},{"key":"11176_CR13","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.immuni.2014.03.012","volume":"40","author":"E Zigmond","year":"2014","unstructured":"Zigmond, E. et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. Immunity 40, 720\u2013733 https:\/\/doi.org\/10.1016\/j.immuni.2014.03.012 (2014).","journal-title":"Immunity"},{"key":"11176_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cyto.2014.10.031","volume":"74","author":"A Saxena","year":"2015","unstructured":"Saxena, A. et al. Interleukin-10 paradox: a potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine 74, 27\u201334 https:\/\/doi.org\/10.1016\/j.cyto.2014.10.031 (2015).","journal-title":"Cytokine"},{"key":"11176_CR15","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.4049\/jimmunol.169.4.2204","volume":"169","author":"H Tilg","year":"2002","unstructured":"Tilg, H., Ulmer, H., Kaser, A. & Weiss, G. Role of IL-10 for induction of anemia during inflammation. J. Immunol. 169, 2204\u20132209 https:\/\/doi.org\/10.4049\/jimmunol.169.4.2204 (2002).","journal-title":"J. Immunol."},{"key":"11176_CR16","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.ccell.2018.10.007","volume":"34","author":"A Naing","year":"2018","unstructured":"Naing, A. et al. PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8+T cell invigoration and polyclonal T cell expansion in cancer patients. Cancer Cell 34, 775\u2013791 https:\/\/doi.org\/10.1016\/j.ccell.2018.10.007 (2018).","journal-title":"Cancer Cell"},{"key":"11176_CR17","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/S1470-2045(19)30514-5","volume":"20","author":"A Naing","year":"2019","unstructured":"Naing, A. et al. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 20, 1544\u20131555 https:\/\/doi.org\/10.1016\/S1470-2045(19)30514-5 (2019).","journal-title":"Lancet Oncol."},{"key":"11176_CR18","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.trecan.2023.05.003","volume":"9","author":"MA Salkeni","year":"2023","unstructured":"Salkeni, M. A. & Naing, A. Interleukin-10 in cancer immunotherapy: from bench to bedside. Trends Cancer 9, 716\u2013725 https:\/\/doi.org\/10.1016\/j.trecan.2023.05.003 (2023).","journal-title":"Trends Cancer"},{"key":"11176_CR19","doi-asserted-by":"publisher","first-page":"13552","DOI":"10.1074\/jbc.275.18.13552","volume":"275","author":"K Josephson","year":"2000","unstructured":"Josephson, K. et al. Design and analysis of an engineered human interleukin-10 monomer. J. Biol. Chem. 275, 13552\u201313557 https:\/\/doi.org\/10.1074\/jbc.275.18.13552 (2000).","journal-title":"J. Biol. Chem."},{"key":"11176_CR20","doi-asserted-by":"publisher","unstructured":"Saxton, R. A. et al. Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10. Science 371, eabc8433 https:\/\/doi.org\/10.1126\/science.abc8433 (2021).","DOI":"10.1126\/science.abc8433"},{"key":"11176_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112201","volume":"42","author":"NA Caveney","year":"2023","unstructured":"Caveney, N. A. et al. Structural basis of Janus kinase trans-activation. Cell Rep. 42, 112201 https:\/\/doi.org\/10.1016\/j.celrep.2023.112201 (2023).","journal-title":"Cell Rep."},{"key":"11176_CR22","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/s41589-022-01098-0","volume":"18","author":"ME Kavanagh","year":"2022","unstructured":"Kavanagh, M. E. et al. Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine. Nat. Chem. Biol. 18, 1388\u20131398 https:\/\/doi.org\/10.1038\/s41589-022-01098-0 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"11176_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/s1074-7613(01)00169-8","volume":"15","author":"K Josephson","year":"2001","unstructured":"Josephson, K., Logsdon, N. J. & Walter, M. R. Crystal structure of the IL-10\/IL-10R1 complex reveals a shared receptor binding site. Immunity 15, 35\u201346 https:\/\/doi.org\/10.1016\/s1074-7613(01)00169-8 (2001).","journal-title":"Immunity"},{"key":"11176_CR24","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/s1074-7613(00)00055-8","volume":"13","author":"K Shimoda","year":"2000","unstructured":"Shimoda, K. et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 13, 561\u2013571 https:\/\/doi.org\/10.1016\/s1074-7613(00)00055-8 (2000).","journal-title":"Immunity"},{"key":"11176_CR25","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1056\/NEJMoa2312302","volume":"391","author":"H Griffin","year":"2024","unstructured":"Griffin, H. et al. Neutralizing autoantibodies against interleukin-10 in inflammatory bowel disease. N. Engl. J. Med. 391, 434\u2013441 https:\/\/doi.org\/10.1056\/NEJMoa2312302 (2024).","journal-title":"N. Engl. J. Med."},{"key":"11176_CR26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41577-025-01207-9","volume":"25","author":"AC Chan","year":"2025","unstructured":"Chan, A. C., Martyn, G. D. & Carter, P. J. Fifty years of monoclonals: the past, present and future of antibody therapeutics. Nat. Rev. Immunol. 25, 745\u2013765 https:\/\/doi.org\/10.1038\/s41577-025-01207-9 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"11176_CR27","doi-asserted-by":"publisher","unstructured":"Bloch, J. S. et al. Development of a universal nanobody-binding Fab module for fiducial-assisted cryo-EM studies of membrane proteins. Proc. Natl Acad. Sci. USA 118, e2115435118 https:\/\/doi.org\/10.1073\/pnas.2115435118 (2021).","DOI":"10.1073\/pnas.2115435118"},{"key":"11176_CR28","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.immuni.2017.02.017","volume":"46","author":"JL Mendoza","year":"2017","unstructured":"Mendoza, J. L. et al. The IFN-\u03bb-IFN-\u03bbR1-IL-10R\u03b2 complex reveals structural features underlying type III IFN functional plasticity. Immunity 46, 379\u2013392 https:\/\/doi.org\/10.1016\/j.immuni.2017.02.017 (2017).","journal-title":"Immunity"},{"key":"11176_CR29","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.immuni.2021.03.008","volume":"54","author":"RA Saxton","year":"2021","unstructured":"Saxton, R. A. et al. The tissue protective functions of interleukin-22 can be decoupled from pro-inflammatory actions through structure-based design. Immunity 54, 660\u2013672 https:\/\/doi.org\/10.1016\/j.immuni.2021.03.008 (2021).","journal-title":"Immunity"},{"key":"11176_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10875-022-01366-7","volume":"43","author":"D Aschenbrenner","year":"2023","unstructured":"Aschenbrenner, D. et al. Pathogenic interleukin-10 receptor alpha variants in humans\u2014balancing natural selection and clinical implications. J. Clin. Immunol. 43, 495\u2013511 https:\/\/doi.org\/10.1007\/s10875-022-01366-7 (2023).","journal-title":"J. Clin. Immunol."},{"key":"11176_CR31","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.immuni.2019.03.028","volume":"50","author":"WJ Leonard","year":"2019","unstructured":"Leonard, W. J., Lin, J. X. & O\u2019Shea, J. J. The \u03b3c family of cytokines: basic biology to therapeutic ramifications. Immunity 50, 832\u2013850 https:\/\/doi.org\/10.1016\/j.immuni.2019.03.028 (2019).","journal-title":"Immunity"},{"key":"11176_CR32","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1002\/(SICI)1521-4141(199909)29:09<2658::AID-IMMU2658>3.0.CO;2-G","volume":"29","author":"G Cai","year":"1999","unstructured":"Cai, G., Kastelein, R. A. & Hunter, C. A. IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-\u03b3 when combined with IL-18. Eur. J. Immunol. 29, 2658\u20132665 (1999).","journal-title":"Eur. J. Immunol."},{"key":"11176_CR33","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.4049\/jimmunol.147.11.3815","volume":"147","author":"DF Fiorentino","year":"1991","unstructured":"Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M. & O\u2019Garra, A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147, 3815\u20133822 (1991).","journal-title":"J. Immunol."},{"key":"11176_CR34","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1172\/JCI118290","volume":"96","author":"DJ Berg","year":"1995","unstructured":"Berg, D. J. et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J. Clin. Invest. 96, 2339\u20132347 https:\/\/doi.org\/10.1172\/JCI118290 (1995).","journal-title":"J. Clin. Invest."},{"key":"11176_CR35","doi-asserted-by":"publisher","first-page":"e2404","DOI":"10.1371\/journal.pone.0002404","volume":"3","author":"Y Iwai","year":"2008","unstructured":"Iwai, Y. et al. An IFN-\u03b3-IL-18 signaling loop accelerates memory CD8+ T cell proliferation. PLoS ONE 3, e2404 https:\/\/doi.org\/10.1371\/journal.pone.0002404 (2008).","journal-title":"PLoS ONE"},{"key":"11176_CR36","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/s41586-025-09393-1","volume":"645","author":"Y Zhao","year":"2025","unstructured":"Zhao, Y. et al. Expanding the cytokine receptor alphabet reprograms T cells into diverse states. Nature 645, 1039\u20131050 https:\/\/doi.org\/10.1038\/s41586-025-09393-1 (2025).","journal-title":"Nature"},{"key":"11176_CR37","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.cell.2022.02.025","volume":"185","author":"M Yen","year":"2022","unstructured":"Yen, M. et al. Facile discovery of surrogate cytokine agonists. Cell 185, 1414\u20131430 https:\/\/doi.org\/10.1016\/j.cell.2022.02.025 (2022).","journal-title":"Cell"},{"key":"11176_CR38","doi-asserted-by":"crossref","unstructured":"Hust, M. & Lim, T. S. Phage Display: Methods and Protocols 2nd edn (Humana Press, 2023).","DOI":"10.1007\/978-1-0716-3381-6"},{"key":"11176_CR39","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 https:\/\/doi.org\/10.1038\/nmeth.4169 (2017).","journal-title":"Nat. Methods"},{"key":"11176_CR40","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 https:\/\/doi.org\/10.1038\/s41586-021-03819-2 (2021).","journal-title":"Nature"},{"key":"11176_CR41","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2014a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 https:\/\/doi.org\/10.1002\/jcc.20084 (2004).","journal-title":"J. Comput. Chem."},{"key":"11176_CR42","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486\u2013501 https:\/\/doi.org\/10.1107\/S0907444910007493 (2010).","journal-title":"Acta Crystallogr. D"},{"key":"11176_CR43","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1107\/S2059798318006551","volume":"74","author":"PV Afonine","year":"2018","unstructured":"Afonine, P. V. et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr. D 74, 531\u2013544 https:\/\/doi.org\/10.1107\/S2059798318006551 (2018).","journal-title":"Acta Crystallogr. D"},{"key":"11176_CR44","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nbt.3820","volume":"35","author":"P Di Tommaso","year":"2017","unstructured":"Di Tommaso, P. et al. Nextflow enables reproducible computational workflows. Nat. Biotechnol. 35, 316\u2013319 https:\/\/doi.org\/10.1038\/nbt.3820 (2017).","journal-title":"Nat. Biotechnol."},{"key":"11176_CR45","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1093\/bioinformatics\/btab135","volume":"37","author":"A Graubert","year":"2021","unstructured":"Graubert, A., Aguet, F., Ravi, A., Ardlie, K. G. & Getz, G. RNA-SeQC 2: efficient RNA-seq quality control and quantification for large cohorts. Bioinformatics 37, 3048\u20133050 https:\/\/doi.org\/10.1093\/bioinformatics\/btab135 (2021).","journal-title":"Bioinformatics"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-11176-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-11176-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-11176-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:10:14Z","timestamp":1792663814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-11176-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":45,"alternative-id":["11176"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-11176-1","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All of the authors are current or former employees of Gilead Sciences and may hold stock or stock options in the company. C.C., L.C., G.D., H.H., M.L.K., C.V.L., N.S.O., H.X., T.Y. and L.Y. are listed as inventors on published patent WO2026112287 (Single immunoglobulin domain bispecific antibodies against IL-10R alpha and beta subunits and methods of use).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}